ARTICLE SUMMARY:
One of only a handful of companies to be approved for this year’s New Technology Add-on Payment program, Impulse Dynamics reveals how achieving Breakthrough technology status can help ease a company’s route to added reimbursement, and how it benefited from the MACs’ recent positive reversal on Category III code coverage.
Enabling reimbursement to keep pace with technology innovation has been a longstanding challenge for the medtech industry. Payors in the US, sometimes including CMS, have typically lagged well behind the introduction of newly FDA-approved/cleared products, resulting in hospitals being reluctant to purchase these devices, clinicians’ being slow to adopt them, and patients—particularly those relying on Medicare—often being denied the benefits of these advanced technologies.
